Supernus Pharmaceuticals (SUPN) reported $149.82 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 4.3%. EPS of $0.42 for the same period compares to $0.00 a year ago.
The reported revenue represents a surprise of +2.91% over the Zacks Consensus Estimate of $145.59 million. With the consensus EPS estimate being $0.38, the EPS surprise was +10.53%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Supernus performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Net product sales- Trokendi XR: $12.80 million compared to the $8.58 million average estimate based on three analysts. The reported number represents a change of -20% year over year.
- Revenues- Net product sales- Oxtellar XR: $10.20 million compared to the $12.29 million average estimate based on three analysts. The reported number represents a change of -62.1% year over year.
- Revenues- Net product sales- Qelbree: $64.70 million versus the three-analyst average estimate of $65.54 million. The reported number represents a year-over-year change of +43.5%.
- Revenues- Net product sales: $141.99 million versus the three-analyst average estimate of $140.61 million. The reported number represents a year-over-year change of +2.6%.
- Revenues- Royalty revenues: $7.84 million versus $5.80 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +51.2% change.
- Revenues- Net product sales- GOCOVRI: $30.70 million versus the three-analyst average estimate of $30.13 million. The reported number represents a year-over-year change of +15.9%.
- Revenues- Net product sales- Other: $8.60 million versus the two-analyst average estimate of $7.38 million. The reported number represents a year-over-year change of +19.4%.
- Revenues- Net product sales- APOKYN: $15 million versus $16.70 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -10.2% change.
View all Key Company Metrics for Supernus here>>>
Shares of Supernus have returned +0.4% over the past month versus the Zacks S&P 500 composite's +11.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Supernus Pharmaceuticals, Inc. (SUPN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
